Michal Juraska
Overview
Explore the profile of Michal Juraska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hesselman M, Zeeb M, Rusert P, Pasin C, Mamrosh J, Kariuki S, et al.
Cell Host Microbe
. 2025 Feb;
33(2):279-293.e6.
PMID: 39909038
Identifying HIV-1 envelope (Env) traits associated with neutralization cross-reactivity is crucial for vaccine design. Variable loops 1 and 2 (V1V2), positioned at the Env trimer apex, are key regions linked...
2.
Cohen P, Lambson B, Mkhize N, Moodley C, Yssel A, Moyo-Gwete T, et al.
J Virol
. 2025 Jan;
99(2):e0173024.
PMID: 39817771
The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against...
3.
Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D, et al.
Nat Commun
. 2024 Nov;
15(1):9785.
PMID: 39532861
Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels...
4.
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, Sawant S, et al.
EBioMedicine
. 2024 Sep;
108:105320.
PMID: 39236556
Background: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based...
5.
Gray G, Mngadi K, Lavreys L, Nijs S, B Gilbert P, Hural J, et al.
Lancet Infect Dis
. 2024 Jul;
24(11):1201-1212.
PMID: 39038477
Background: HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective...
6.
Juraska M, Early A, Li L, Schaffner S, Lievens M, Khorgade A, et al.
Lancet Infect Dis
. 2024 May;
24(9):1025-1036.
PMID: 38723650
Background: The first licensed malaria vaccine, RTS,S/AS01, confers moderate protection against symptomatic disease. Because many malaria infections are asymptomatic, we conducted a large-scale longitudinal parasite genotyping study of samples from...
7.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2024 Mar;
15(1):2575.
PMID: 38519455
No abstract available.
8.
Magaret C, Li L, deCamp A, Rolland M, Juraska M, Williamson B, et al.
Nat Commun
. 2024 Mar;
15(1):2175.
PMID: 38467646
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine...
9.
Juraska M, Bai H, deCamp A, Magaret C, Li L, Gillespie K, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(4):e2308942121.
PMID: 38241441
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition...
10.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2023 Dec;
14(1):8299.
PMID: 38097552
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical...